Abstract:Background Overexpression of Aurora A and B has been reported in a wide range of tumor types, including gastric cancer. Anti-angiogenesis has been considered as an important therapeutic modality in advanced gastric cancer. Here we identified a novel compound TY-011 with promising antitumor activity by targeting mitotic kinases (Aurora A and B) and angiogenic receptor tyrosine kinase (VEGFR2). Methods HTRF® KinEASE™ assay was used to detect the effect of TY-011 against Aurora A, Aurora B and VEGFR2 activities. Docking simulation study was performed to predict the binding mode of TY-011 with Aurora A and B kinases. CCK-8 assay was used to test cell growth. Cell cycle and cell apoptosis was analyzed by flow cytometry. Gastric cancer cell xenograft mouse models were used for in vivo study. TUNEL kit was used to determine the apoptosis of tumor tissues. Immunohistochemistry analysis and HUVEC tube formation assay were performed to determine the anti-angiogenesis ability. Immunofluorescence and western blot were used to test protein expression. Results TY-011 was identified as a potential Aurora A and B inhibitor by HTRF® KinEASE™ assay. It effectively inhibited cellular Aurora A and B activities in a concentration-dependent manner. TY-011 occupied the ATP-binding site of both Aurora A and B kinases. TY-011 demonstrated prominent inhibitory effects on proliferation of gastric cancer cells. TY-011 treatment induced an obvious accumulation of cells at G2/M phase and a modest increase of cells with >4 N DNA content, which then underwent apoptosis. Meaningfully, orally administration of TY-011 demonstrated superior efficacy against the tumor growth in gastric cancer cell xenograft, with ~90% inhibition rate and 100% tumor regression at 9 mg/kg dose, and TY-011 did not affect the body weight of mice. Interestingly, we observed that TY-011 also antagonized tumor angiogenesis by targeting VEGFR2 kinase. Conclusions These results indicate that TY-011 is a well-tolerated, orally active compound that targets mitosis and angiogenesis in tumor growth, and provides strong preclinical support for use as a therapeutic for human gastric cancers.

YLT192, a Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models

The Novel Vegf Receptor 2 Inhibitor Yll545 Inhibits Angiogenesis and Growth in Breast Cancer

A Novel Synthetic Small Molecule YF-452 Inhibits Tumor Growth Through Antiangiogenesis by Suppressing VEGF Receptor 2 Signaling

Yl529, A Novel, Orally Available Multikinase Inhibitor, Potently Inhibits Angiogenesis And Tumour Growth In Preclinical Models

Lyg-202, A Newly Synthesized Flavonoid, Exhibits Potent Anti-Angiogenic Activity in Vitro and in Vivo

SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.

Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases

Yn968d1 Is A Novel And Selective Inhibitor Of Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase With Potent Activity In Vitro And In Vivo

A small molecular agent YL529 inhibits VEGF-D-induced lymphangiogenesis and metastasis in preclinical tumor models in addition to its known antitumor activities

Discovery of a Highly Selective VEGFR2 Kinase Inhibitor CHMFL-VEGFR2-002 As a Novel Anti-Angiogenesis Agent

Xanthatin, a Novel Potent Inhibitor of VEGFR2 Signaling, Inhibits Angiogenesis and Tumor Growth in Breast Cancer Cells.

Sklb1002, A Novel Inhibitor of Vegf Receptor 2 Signaling, Induces Vascular Normalization to Improve Systemically Administered Chemotherapy Efficacy

Abstract 4259: Preclinical Anti-Tumor Study of Henatinib, a Novel and Selective Inhibitor of VEGFR-2 in Phase I Clinical Trials

LYG-202 Inhibits Activation of Endothelial Cells and Angiogenesis Through CXCL12/CXCR7 Pathway in Breast Cancer

Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines.

A Novel Angiogenesis Inhibitor Impairs Lovo Cell Survival Via Targeting Against Human VEGFR and Its Signaling Pathway of Phosphorylation

Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1.

SKLB-287, a Novel Oral Multikinase Inhibitor of EGFR and VEGFR2, Exhibits Potent Antitumor Activity in LoVo Colorectal Tumor Model.

Design, Synthesis and Pharmacological Evaluation of Novel 4-Phenoxyquinoline Derivatives as VEGFR2 Kinase Inhibitors for Tumor Treatment

Design, synthesis and biological evaluation of indazole derivatives as VEGFR-2 kinase inhibitors with anti-angiogenic properties

Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect